Carcinogenic activity in rats of combined treatment with cyclophosphamide, methotrexate and 5-fluorouracil.
A total of 240 outbred Sprague-Dawley rats were treated with 3 different doses of the cyclophosphamide-methotrexate-5-fluorouracil (CMF) regimen adopted from clinical chemotherapy studies in breast cancer patients. Eighty untreated rats served as controls. Individual and total doses of the drugs applied were lower than corresponding doses used in human adjuvant therapy protocols compared on a mg/m2 basis. Lifelong observation of the animals demonstrated a strong dose-related carcinogenic response to the tested scheme. Main target organs of treatment-related neoplasms were the nervous system, the hematopoietic and lymphatic tissue, the urinary bladder, and the suprarenal gland. It is concluded that the CMF drug combination evokes carcinogenic responses in several organ systems in the rat and should be regarded as representing a carcinogenic risk to humans. Uncritical clinical use of the three-drug protocol should be avoided.
D000310:Adrenal Gland Neoplasms / Q000139:chemically induced; D000818:Animals; D003520:Cyclophosphamide / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects*; D006801:Humans; D007942:Leukemia, Experimental / Q000139:chemically induced; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects*; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D009423:Nervous System Neoplasms / Q000139:chemically induced; D051381:Rats; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate